364 related articles for article (PubMed ID: 33919281)
1. Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers.
Toss A; Tenedini E; Piombino C; Venturelli M; Marchi I; Gasparini E; Barbieri E; Razzaboni E; Domati F; Caggia F; Grandi G; Combi F; Tazzioli G; Dominici M; Tagliafico E; Cortesi L
Genes (Basel); 2021 Apr; 12(5):. PubMed ID: 33919281
[TBL] [Abstract][Full Text] [Related]
2. Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations.
Sokolenko AP; Bogdanova N; Kluzniak W; Preobrazhenskaya EV; Kuligina ES; Iyevleva AG; Aleksakhina SN; Mitiushkina NV; Gorodnova TV; Bessonov AA; Togo AV; Lubiński J; Cybulski C; Jakubowska A; Dörk T; Imyanitov EN
Breast Cancer Res Treat; 2014 Jun; 145(2):553-62. PubMed ID: 24800916
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical findings and clinicopathological features of breast cancers with pathogenic germline mutations in Non-BRCA genes.
Singh K; Scalia J; Legare R; Quddus MR; Sung CJ
Hum Pathol; 2024 Apr; 146():49-56. PubMed ID: 38608781
[TBL] [Abstract][Full Text] [Related]
4. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
Cragun D; Weidner A; Tezak A; Clouse K; Pal T
Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
[TBL] [Abstract][Full Text] [Related]
5. Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in
Yadav S; Boddicker NJ; Na J; Polley EC; Hu C; Hart SN; Gnanaolivu RD; Larson N; Holtegaard S; Huang H; Dunn CA; Teras LR; Patel AV; Lacey JV; Neuhausen SL; Martinez E; Haiman C; Chen F; Ruddy KJ; Olson JE; John EM; Kurian AW; Sandler DP; O'Brien KM; Taylor JA; Weinberg CR; Anton-Culver H; Ziogas A; Zirpoli G; Goldgar DE; Palmer JR; Domchek SM; Weitzel JN; Nathanson KL; Kraft P; Couch FJ
J Clin Oncol; 2023 Mar; 41(9):1703-1713. PubMed ID: 36623243
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathologic and genetic analysis of invasive breast carcinomas in women with germline CHEK2 variants.
Schwartz CJ; Khorsandi N; Blanco A; Mukhtar RA; Chen YY; Krings G
Breast Cancer Res Treat; 2024 Feb; 204(1):171-179. PubMed ID: 38091153
[TBL] [Abstract][Full Text] [Related]
7. Radiation Treatment, ATM, BRCA1/2, and CHEK2*1100delC Pathogenic Variants and Risk of Contralateral Breast Cancer.
Reiner AS; Robson ME; Mellemkjær L; Tischkowitz M; John EM; Lynch CF; Brooks JD; Boice JD; Knight JA; Teraoka SN; Liang X; Woods M; Shen R; Shore RE; Stram DO; Thomas DC; Malone KE; Bernstein L; Riaz N; Woodward W; Powell S; Goldgar D; Concannon P; ; Bernstein JL
J Natl Cancer Inst; 2020 Dec; 112(12):1275-1279. PubMed ID: 32119081
[TBL] [Abstract][Full Text] [Related]
8. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
[TBL] [Abstract][Full Text] [Related]
9. Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model.
Lee AJ; Cunningham AP; Tischkowitz M; Simard J; Pharoah PD; Easton DF; Antoniou AC
Genet Med; 2016 Dec; 18(12):1190-1198. PubMed ID: 27464310
[TBL] [Abstract][Full Text] [Related]
10. Germline CHEK2 Gene Mutations in Hereditary Breast Cancer Predisposition - Mutation Types and their Biological and Clinical Relevance.
Kleiblová P; Stolařová L; Křížová K; Lhota F; Hojný J; Zemánková P; Havránek O; Vočka M; Černá M; Lhotová K; Borecká M; Janatová M; Soukupová J; Ševčík J; Zimovjanová M; Kotlas J; Panczak A; Veselá K; Červenková J; Schneiderová M; Burócziová M; Burdová K; Stránecký V; Foretová L; Macháčková E; Tavandzis S; Kmoch S; Macůrek L; Kleibl Z
Klin Onkol; 2019; 32(Supplementum2):36-50. PubMed ID: 31409080
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive Breast Cancer Risk Assessment for
Gallagher S; Hughes E; Kurian AW; Domchek SM; Garber J; Probst B; Morris B; Tshiaba P; Meek S; Rosenthal E; Roa B; Slavin TP; Wagner S; Weitzel J; Gutin A; Lanchbury JS; Robson M
JCO Precis Oncol; 2021 Jun; 5():. PubMed ID: 34322652
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer screening implications of risk modeling among female relatives of ATM and CHEK2 carriers.
Weidner AE; Liggin ME; Zuniga BI; Tezak AL; Wiesner GL; Pal T
Cancer; 2020 Apr; 126(8):1651-1655. PubMed ID: 31967672
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological Features and Outcomes in Individuals with Breast Cancer and ATM, CHEK2, or PALB2 Mutations.
Bergstrom C; Pence C; Berg J; Partain N; Sadeghi N; Mauer C; Pirzadeh-Miller S; Gao A; Li H; Unni N; Syed S
Ann Surg Oncol; 2021 Jun; 28(6):3383-3393. PubMed ID: 32996020
[TBL] [Abstract][Full Text] [Related]
14. Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D.
Graffeo R; Rana HQ; Conforti F; Bonanni B; Cardoso MJ; Paluch-Shimon S; Pagani O; Goldhirsch A; Partridge AH; Lambertini M; Garber JE
Breast; 2022 Oct; 65():32-40. PubMed ID: 35772246
[TBL] [Abstract][Full Text] [Related]
15. Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies.
Stubbins RJ; Korotev S; Godley LA
Curr Hematol Malig Rep; 2022 Aug; 17(4):94-104. PubMed ID: 35674998
[TBL] [Abstract][Full Text] [Related]
16. The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers.
Weigelt B; Bi R; Kumar R; Blecua P; Mandelker DL; Geyer FC; Pareja F; James PA; ; Couch FJ; Eccles DM; Blows F; Pharoah P; Li A; Selenica P; Lim RS; Jayakumaran G; Waddell N; Shen R; Norton L; Wen HY; Powell SN; Riaz N; Robson ME; Reis-Filho JS; Chenevix-Trench G
J Natl Cancer Inst; 2018 Sep; 110(9):1030-1034. PubMed ID: 29506079
[TBL] [Abstract][Full Text] [Related]
17. Rare, protein-truncating variants in
Decker B; Allen J; Luccarini C; Pooley KA; Shah M; Bolla MK; Wang Q; Ahmed S; Baynes C; Conroy DM; Brown J; Luben R; Ostrander EA; Pharoah PD; Dunning AM; Easton DF
J Med Genet; 2017 Nov; 54(11):732-741. PubMed ID: 28779002
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and characterization of ATM germline mutations in Chinese BRCA1/2-negative breast cancer patients.
Yang Z; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Zhang J; Xie Y
Breast Cancer Res Treat; 2019 Apr; 174(3):639-647. PubMed ID: 30607632
[TBL] [Abstract][Full Text] [Related]
19. High risk of breast cancer in women with biallelic pathogenic variants in CHEK2.
Rainville I; Hatcher S; Rosenthal E; Larson K; Bernhisel R; Meek S; Gorringe H; Mundt E; Manley S
Breast Cancer Res Treat; 2020 Apr; 180(2):503-509. PubMed ID: 31993860
[TBL] [Abstract][Full Text] [Related]
20. Development of breast tumors in CHEK2, NBN/NBS1 and BLM mutation carriers does not commonly involve somatic inactivation of the wild-type allele.
Suspitsin EN; Yanus GA; Sokolenko AP; Yatsuk OS; Zaitseva OA; Bessonov AA; Ivantsov AO; Heinstein VA; Klimashevskiy VF; Togo AV; Imyanitov EN
Med Oncol; 2014 Feb; 31(2):828. PubMed ID: 24415413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]